All In MedTech

Device Trial Radar · NCT03684408

Radiofrequency Chip for Localization of Non-Palpable Breast Lesions

Use of a Radiofrequency Chip for Localization of Non-Palpable Breast Lesions: A Comparison to Wire Localization

Last checked: Nov 19, 2026Latest source record: Aug 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

38

Actual

Start

Oct 18, 2018

Primary completion

Apr 19, 2021

Study completion Apr 19, 2021

Sponsor

Lead sponsor
University of Missouri-ColumbiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Health Beacons
First posted
Sep 25, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the project is to compare Radiofrequency identification device (RFID) localization technique with the current clinical standard wire localization technique. The Investigator's hypotheses is that the RFID localization technique is non-inferior to wire localization for breast lesions (tumors). The study will be conducted in two parts. The purpose of Part A is for physician training with the RFID device. Nine subjects will undergo RFID and wire localization prior to breast lesion excision. This will allow the breast radiologists and surgeons to become comfortable with RFID device placement and retrieval. Additionally, the investigators will pilot the data collection surveys and chart review methodology to be used in Part B. The purpose of Part B is to conduct a randomized clinical trial to assess whether RFID localization is non-inferior to wire localization for breast lesions. For this part, sixty subjects will be randomized to RFID (N=30) or wire localization (N=30) at time of enrollment. Surveys will be used to gather data from participants, radiologists, surgeons, and technologists/mammography nurses. A variety of data will be collected including, but not limited to, information on tumor size, location, depth; subject demographics; adequacy of tumor margins, re-excision rates, accuracy of wire or chip placement, and surgical complications.

Conditions

  • Breast Tumor

Interventions

  • RFID LocalizationDevice

    The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.

  • Wire LocalizationDevice

    The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.

  • RFID and Wire LocalizationDevice

    Both RFID and the standard of care wire localization will be performed for physician training.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Successful LocalizationTime frame: From the date of localization through the date of surgery up to 4 weeks; data collected during Visit 3 at time of surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Missouri

    Columbia, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.